T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.

ABSTRACT:

Background

T cell receptor (TCR)-engineered cells can be powerful tools in the treatment of malignancies. However, tumor resistance by Human Leukocyte antigen (HLA) class I downregulation can negatively impact the success of any TCR-mediated cell therapy. Allogeneic natural killer (NK) cells have demonstrated efficacy and safety against malignancies without inducing graft-versus-host-disease, highlighting the feasibility for an 'off the shelf' cellular therapeutic. Furthermore, primary NK cells can target tumors using a broad array of intrinsic activation mechanisms. In this study, we combined the antitumor effector functions of NK cells with TCR engineering (NK-TCR), creating a novel therapeutic strategy to avoid TCR-associated immune resistance.

Methods

BOB1, is a transcri

SUBMITTER: Morton LT 

PROVIDER: S-EPMC8921915 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature